Managed Care,
Software,
Other Health,
General Health,
Mobile,
Wireless,
Telemedicine,
Virtual Medicine,
Apps,
Applications,
Technology,
Medical Devices,
Artificial Intelligence,
Fitness & Nutrition,
Surgery,
Health,
Digital health,
Patient,
Obesity,
Bariatric surgery,
Internal medicine,
Artificial intelligence,
VCS,
Gastroenterology,
AI,
Attention,
Communication,
Weight loss,
Entrepreneurship,
Medical device They can also engage with Coach Iris for tailored meal plans, recipes, exercise routines, stress management techniques, and motivational insights.
Key Points:
- They can also engage with Coach Iris for tailored meal plans, recipes, exercise routines, stress management techniques, and motivational insights.
- Coach Iris is part of the VCS, a dynamic weight-loss management suite powered by AI and featuring remote patient monitoring, predictive analytics, telehealth, and care team collaboration.
- The VCS is available to healthcare professionals offering GLP-1 and other anti-obesity medication therapy, bariatric surgery, and weight loss devices.
- We immediately saw the immense value of Coach Iris and how it will help our patients stay engaged throughout their weight loss journey,” said Paul Barros, Co-Founder and CEO of Pivot Weight Loss .
Software,
Other Health,
General Health,
Data Management,
Apps,
Applications,
Technology,
Medical Devices,
Health Technology,
Fitness & Nutrition,
Public Relations,
Investor Relations,
Biotechnology,
Communications,
Health,
Obesity Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will be participating in two upcoming investor conferences:
Key Points:
Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will be participating in two upcoming investor conferences:
Health Technology,
Fitness & Nutrition,
Health,
Surgery,
Patient,
E pluribus unum,
ECO,
Composition,
Interest,
Bariatric surgery,
Gaur,
European,
Uptake,
Center of mass,
Facial muscles,
Congress,
Caloric deficit,
Sustainability,
Body composition,
Behavior,
Weight loss,
Skeletal muscle,
Dietary supplement Presentations include data from a study of 712 patients treated with the Allurion Program, which is anchored by the Allurion Balloon and enhanced by the Virtual Care Suite featuring Allurion’s proprietary behavior change program.
Key Points:
- Presentations include data from a study of 712 patients treated with the Allurion Program, which is anchored by the Allurion Balloon and enhanced by the Virtual Care Suite featuring Allurion’s proprietary behavior change program.
- “The Allurion Program was designed to monitor both weight loss and lean body mass, facilitate basic changes in behavior that can protect skeletal muscle, and reduce the impact on lean body mass during periods of rapid weight loss,” said Dr. Shantanu Gaur, Founder and CEO of Allurion.
- For example, GLP-1s have been shown to lead to approximately 40% lean body mass loss at one year of treatment.1,2
“Maintaining lean body mass in the setting of significant caloric deficit is a challenge.
- We believe the Allurion Program makes this possible with its body composition monitoring and a personalized program that focuses on outcomes beyond just weight,” said Dr. Ram Chuttani, Chief Medical Officer of Allurion.
Apps,
Applications,
Technology,
Fitness & Nutrition,
Health Technology,
Software,
Other Health,
Biotechnology,
General Health,
Health,
Data Management,
Obstructive sleep apnea,
LP,
Investment,
Obesity,
Telephone,
Gaur,
VCS,
Marketing,
Conference,
Total,
Hypertension,
Growth,
Attention,
Research,
RTW,
NHS Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the first quarter ended March 31, 2024, and provided a business update.
Key Points:
- Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the first quarter ended March 31, 2024, and provided a business update.
- Gross profit as a percent of sales was 73% for the first quarter, compared to 79% for the same period in 2023.
- Loss from operations for the first quarter was $11.4 million compared to $13.9 million in the same period in 2023.
- For full year 2024, Allurion reiterates the financial guidance it previously published:
Revenue of $60 to $65 million, reflecting 13-23% growth year-over-year
Company management will host a conference call to discuss financial results and provide a business update on May 14, 2024 at 8:30 AM ET.
Diabetes,
General Health,
Fitness & Nutrition,
Health,
Doctor of Philosophy,
Congress,
Virtual,
AI,
Bariatric surgery,
Fidelity,
Weight loss,
Metabolism,
Patient,
Society,
DSM-IV codes,
Karger Publishers,
Evolution,
Behavior,
Gastric balloon In addition, 72% of patients reported that three years after the Program, their eating habits had remained healthier.
Key Points:
- In addition, 72% of patients reported that three years after the Program, their eating habits had remained healthier.
- "Long-term weight maintenance after significant weight loss is notoriously difficult to achieve,” said Dr. Shantanu Gaur, Founder and CEO of Allurion.
- “The Allurion Program is intended to deliver a significant amount of weight loss in a short period of time and simultaneously help individuals make durable changes to their lifestyle and behavior.
- Ienca R et al., The Evolution of the Allurion Program for Long-Term Weight Loss: From Virtual Monitoring to a Virtual Care Suite.
Biotechnology,
Managed Care,
General Health,
Health,
Medical Devices,
Health Technology,
Fitness & Nutrition,
Other Health,
Obesity,
United,
Growth,
Mobile phone Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced preliminary, unaudited results for the first quarter 2024.
Key Points:
- Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced preliminary, unaudited results for the first quarter 2024.
- Management expects preliminary unaudited results for the period as follows:
Revenue in the range of $9.2 million to $9.3 million, reflecting growth of between 12%-13% over the fourth quarter of 2023
Procedural volume growth, as estimated by new app users, reflecting 22% growth over the fourth quarter of 2023
Cash burn in the range of $8 million to $9 million, down from $22 million in the fourth quarter of 2023, and in line with targeted cash burn of approximately $30 million for the year
“We are encouraged by our growth in the first quarter in both revenue and procedural volume, while slowing our cash burn rate,” said Dr. Shantanu Gaur, Founder and Chief Executive Officer.
- “We believe awareness and demand for the Allurion Program will continue to grow in subsequent quarters, and we expect the business to feed off of recent catalysts, including the launch of the Allurion Virtual Care Suite in the United States and the first reimbursed procedures in the United Kingdom.”
The Company will host a conference call on Tuesday, May 14, 2024, at 8:30 AM ET to discuss first quarter financial results and provide a business update.
Retrieved on:
Wednesday, April 17, 2024
Biotechnology,
Pharmaceutical,
Managed Care,
General Health,
Health,
Health Technology,
Fitness & Nutrition,
Other Health,
Partnership,
U.S. FDA,
Growth,
Obesity,
Partner (business rank),
RTW,
Investment Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced the closing of a $48 million convertible senior secured note financing with certain entities managed by RTW Investments, LP (“RTW”).
Key Points:
- Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced the closing of a $48 million convertible senior secured note financing with certain entities managed by RTW Investments, LP (“RTW”).
- "RTW’s investment underscores our shared belief in the long-term potential of the Allurion Program,” said Dr. Shantanu Gaur, Founder and CEO of Allurion.
- The investment furthers our long-term partnership with RTW and provides us additional flexibility to achieve our long-term goals,” Dr. Gaur continued.
- “We are pleased to strengthen our relationship with Allurion as it continues its mission to end obesity around the world.
Women,
Other Health,
Other Technology,
Men,
Telemedicine,
Virtual Medicine,
Family,
Medical Devices,
Hospitals,
Consumer,
Fitness & Nutrition,
Technology,
General Health,
Biotechnology,
Diabetes,
Surgery,
Health,
Apps,
Applications,
Health Technology,
Bariatric surgery,
Conference,
Obesity,
VCS,
Patient,
Research,
Artificial intelligence,
Digital health,
Digital,
NPS,
Satellite navigation device Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the commercial availability of its comprehensive Virtual Care Suite (VCS) in the United States.
Key Points:
- Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the commercial availability of its comprehensive Virtual Care Suite (VCS) in the United States.
- In 2023, Allurion added Coach Iris, a 24/7 AI-powered weight loss coach, to the VCS, enabling automated, conversational coaching and a more personalized behavior change program tailored to patient needs.
- “After witnessing the profound impact our technology has had globally, we are thrilled to launch the VCS in the United States.
- As part of the launch, Allurion will also be unveiling a new version of Allurion Insights, the web-based dashboard that providers use to navigate the VCS.
Health,
General Health,
Research,
Attention,
Conference,
Obesity,
Growth,
Telephone,
Overalls,
PMA,
Preannouncement,
Marketing,
FDA,
Total,
Food,
Pharmaceutical industry Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion”), a company dedicated to ending obesity, today reported financial results for the fourth quarter and full year ended December 31, 2023, and reiterated 2024 guidance.
Key Points:
- Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion”), a company dedicated to ending obesity, today reported financial results for the fourth quarter and full year ended December 31, 2023, and reiterated 2024 guidance.
- “As we begin 2024, this demand has continued to increase, and we have seen improvement in some of the macro conditions that negatively impacted the fourth quarter.
- Gross profit for the fourth quarter was 78% of revenue, compared to 79% of revenue in the same period in 2022.
- For full year 2024, Allurion reiterates the financial guidance it previously published:
Revenue of $60 to $65 million, reflecting 12-22% growth year-over-year
Allurion management will host a conference call at 8:30 a.m.
Retrieved on:
Wednesday, March 13, 2024
Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will be participating in the 34th Annual Oppenheimer Healthcare MedTech & Services Conference, taking place on March 12 - 13, 2024, virtually.
Key Points:
- Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will be participating in the 34th Annual Oppenheimer Healthcare MedTech & Services Conference, taking place on March 12 - 13, 2024, virtually.
- Shantanu Gaur, Allurion’s Chief Executive Officer, and Chris Geberth, Chief Financial Officer, will present today, Wednesday, March 13, 2024 at 4:00 p.m. Eastern Time.
- Management will also participate in 1x1 meetings.
- A live webcast of the event will be available on the Allurion website, under Events & Presentations .
